AI assistant
CONTROL BIONICS LIMITED — Investor Presentation 2025
Nov 11, 2025
64611_rns_2025-11-11_95228aff-e919-45c9-8b82-6de6cec36543.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [177 x 63] intentionally omitted <==
12 November 2025
Investor Briefing: Apple Partnership and Commercial
Progress
Control Bionics Limited (ASX:CBL) , an Australian leader in Electromyography (EMG) medical device technology, invites all investors to join an online Investor Briefing .
The session will provide a company update and discuss the recently announced integration with Apple’s Brain-Computer Interface (BCI) Protocol , including its significance for the Company’s commercial strategy and future growth initiatives.
Please register for this event with the details below:
Date: Thursday, 13 November 2025
Time: 11.00am (AEDT)
Registration link: Click here
This announcement is authorised by the Control Bionics CEO, Jeremy Steele.
About Control Bionics:
Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS).
About NeuroNode
Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.
About NeuroStrip
Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.
Control Bionics has a 22% investment in Neuro Elite Athletics to drive rapid growth of their NeuroBounce program in the US and Australia
Control Bionics Limited
Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121 T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462
==> picture [177 x 63] intentionally omitted <==
Control Bionics operates in North America, Australia, Singapore and Japan.
Investors and Media
Jeremy Steele – CEO and Managing Director [email protected]
Brett Crowley - Company Secretary [email protected]
Investor Relations:
Joe Durak Executive Director & Founder Lynx Advisors [email protected] +61 414 465 582
Control Bionics Limited
Registered Office: Level 4, 11-13 Pearson St, Cremorne, Victoria 3121, Australia T: +61 3 9897 3576
W: www.controlbionics.com
ABN: 45 115 465 462
For further information visit the website: https://www.controlbionics.com/
Control Bionics Limited
Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121 T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462